JP6196241B2 - 生物学的に活性なポリペプチドのハイスループットスクリーニング - Google Patents
生物学的に活性なポリペプチドのハイスループットスクリーニング Download PDFInfo
- Publication number
- JP6196241B2 JP6196241B2 JP2014555774A JP2014555774A JP6196241B2 JP 6196241 B2 JP6196241 B2 JP 6196241B2 JP 2014555774 A JP2014555774 A JP 2014555774A JP 2014555774 A JP2014555774 A JP 2014555774A JP 6196241 B2 JP6196241 B2 JP 6196241B2
- Authority
- JP
- Japan
- Prior art keywords
- cell
- polypeptide
- nucleic acid
- beads
- item
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims description 381
- 102000004196 processed proteins & peptides Human genes 0.000 title claims description 360
- 229920001184 polypeptide Polymers 0.000 title claims description 358
- 238000013537 high throughput screening Methods 0.000 title description 2
- 210000004027 cell Anatomy 0.000 claims description 525
- 239000011324 bead Substances 0.000 claims description 367
- 150000007523 nucleic acids Chemical class 0.000 claims description 316
- 102000039446 nucleic acids Human genes 0.000 claims description 306
- 108020004707 nucleic acids Proteins 0.000 claims description 306
- 238000000034 method Methods 0.000 claims description 301
- 238000012360 testing method Methods 0.000 claims description 260
- 239000000839 emulsion Substances 0.000 claims description 219
- 239000003094 microcapsule Substances 0.000 claims description 218
- 238000009739 binding Methods 0.000 claims description 183
- 230000027455 binding Effects 0.000 claims description 182
- 230000008512 biological response Effects 0.000 claims description 74
- 239000003153 chemical reaction reagent Substances 0.000 claims description 58
- 108090000623 proteins and genes Proteins 0.000 claims description 52
- 102000004169 proteins and genes Human genes 0.000 claims description 47
- 230000004071 biological effect Effects 0.000 claims description 40
- 230000004044 response Effects 0.000 claims description 32
- 230000008859 change Effects 0.000 claims description 25
- 102000004190 Enzymes Human genes 0.000 claims description 20
- 108090000790 Enzymes Proteins 0.000 claims description 20
- 230000000694 effects Effects 0.000 claims description 20
- 230000003834 intracellular effect Effects 0.000 claims description 18
- 238000002372 labelling Methods 0.000 claims description 16
- 108090000672 Annexin A5 Proteins 0.000 claims description 15
- 102000004121 Annexin A5 Human genes 0.000 claims description 15
- 230000006907 apoptotic process Effects 0.000 claims description 14
- 230000003287 optical effect Effects 0.000 claims description 13
- 230000001580 bacterial effect Effects 0.000 claims description 12
- 230000006037 cell lysis Effects 0.000 claims description 12
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 11
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 11
- 102000003939 Membrane transport proteins Human genes 0.000 claims description 10
- 108090000301 Membrane transport proteins Proteins 0.000 claims description 10
- 239000007850 fluorescent dye Substances 0.000 claims description 10
- 230000009061 membrane transport Effects 0.000 claims description 10
- 108700019146 Transgenes Proteins 0.000 claims description 9
- 230000030833 cell death Effects 0.000 claims description 9
- 210000004962 mammalian cell Anatomy 0.000 claims description 8
- 206010028980 Neoplasm Diseases 0.000 claims description 7
- 201000011510 cancer Diseases 0.000 claims description 7
- 210000000130 stem cell Anatomy 0.000 claims description 7
- 241000238631 Hexapoda Species 0.000 claims description 6
- 230000024245 cell differentiation Effects 0.000 claims description 6
- 230000001747 exhibiting effect Effects 0.000 claims description 6
- 230000002538 fungal effect Effects 0.000 claims description 6
- 210000002865 immune cell Anatomy 0.000 claims description 6
- 230000004663 cell proliferation Effects 0.000 claims description 5
- 230000008030 elimination Effects 0.000 claims description 5
- 238000003379 elimination reaction Methods 0.000 claims description 5
- 238000010521 absorption reaction Methods 0.000 claims description 4
- 230000004913 activation Effects 0.000 claims description 4
- 238000004020 luminiscence type Methods 0.000 claims description 4
- 230000001404 mediated effect Effects 0.000 claims description 3
- 210000002569 neuron Anatomy 0.000 claims description 3
- 102000011727 Caspases Human genes 0.000 claims description 2
- 108010076667 Caspases Proteins 0.000 claims description 2
- 108020004414 DNA Proteins 0.000 description 150
- 238000003752 polymerase chain reaction Methods 0.000 description 101
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 79
- 239000004094 surface-active agent Substances 0.000 description 56
- 239000000203 mixture Substances 0.000 description 55
- 239000003921 oil Substances 0.000 description 50
- 230000002441 reversible effect Effects 0.000 description 45
- 239000000872 buffer Substances 0.000 description 43
- 239000002245 particle Substances 0.000 description 37
- 229960002685 biotin Drugs 0.000 description 36
- 239000011616 biotin Substances 0.000 description 36
- 238000012216 screening Methods 0.000 description 36
- 235000020958 biotin Nutrition 0.000 description 35
- 239000002480 mineral oil Substances 0.000 description 34
- 239000000523 sample Substances 0.000 description 34
- 238000013519 translation Methods 0.000 description 32
- 239000012071 phase Substances 0.000 description 31
- 239000000047 product Substances 0.000 description 30
- 230000014616 translation Effects 0.000 description 30
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 30
- 108700026244 Open Reading Frames Proteins 0.000 description 29
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 28
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 28
- 108010090804 Streptavidin Proteins 0.000 description 26
- 230000003321 amplification Effects 0.000 description 26
- 238000003199 nucleic acid amplification method Methods 0.000 description 26
- 125000006850 spacer group Chemical group 0.000 description 26
- 108091026890 Coding region Proteins 0.000 description 25
- 102000053602 DNA Human genes 0.000 description 25
- 230000008569 process Effects 0.000 description 25
- 108010051109 Cell-Penetrating Peptides Proteins 0.000 description 23
- 102000020313 Cell-Penetrating Peptides Human genes 0.000 description 23
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 22
- 238000006243 chemical reaction Methods 0.000 description 22
- 238000013518 transcription Methods 0.000 description 22
- 230000035897 transcription Effects 0.000 description 22
- LRHPLDYGYMQRHN-UHFFFAOYSA-N 1-butanol Substances CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 20
- 239000002953 phosphate buffered saline Substances 0.000 description 20
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 19
- 235000010446 mineral oil Nutrition 0.000 description 19
- 239000011541 reaction mixture Substances 0.000 description 19
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 18
- 239000007983 Tris buffer Substances 0.000 description 17
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 17
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 16
- 238000003556 assay Methods 0.000 description 16
- VDXZNPDIRNWWCW-JFTDCZMZSA-N melittin Chemical compound NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(N)=O)CC1=CNC2=CC=CC=C12 VDXZNPDIRNWWCW-JFTDCZMZSA-N 0.000 description 16
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 15
- 108010036176 Melitten Proteins 0.000 description 15
- 108091028043 Nucleic acid sequence Proteins 0.000 description 15
- 239000013504 Triton X-100 Substances 0.000 description 15
- 229920004890 Triton X-100 Polymers 0.000 description 15
- 238000003776 cleavage reaction Methods 0.000 description 15
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 15
- 230000007017 scission Effects 0.000 description 15
- 230000004927 fusion Effects 0.000 description 14
- 239000000499 gel Substances 0.000 description 14
- 239000005090 green fluorescent protein Substances 0.000 description 14
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 13
- 238000010586 diagram Methods 0.000 description 13
- 238000002955 isolation Methods 0.000 description 13
- 229960001225 rifampicin Drugs 0.000 description 13
- 108091034117 Oligonucleotide Proteins 0.000 description 12
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 12
- 241000723792 Tobacco etch virus Species 0.000 description 12
- 239000011230 binding agent Substances 0.000 description 12
- 239000002299 complementary DNA Substances 0.000 description 12
- RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 12
- 238000004945 emulsification Methods 0.000 description 12
- 229940094991 herring sperm dna Drugs 0.000 description 12
- 241000588724 Escherichia coli Species 0.000 description 11
- 101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 description 11
- 101710163270 Nuclease Proteins 0.000 description 11
- 230000001588 bifunctional effect Effects 0.000 description 11
- 239000012528 membrane Substances 0.000 description 11
- 210000004379 membrane Anatomy 0.000 description 11
- 238000012986 modification Methods 0.000 description 11
- 230000004048 modification Effects 0.000 description 11
- 238000012163 sequencing technique Methods 0.000 description 11
- 239000011780 sodium chloride Substances 0.000 description 11
- 238000005406 washing Methods 0.000 description 11
- 108090001090 Lectins Proteins 0.000 description 10
- 102000004856 Lectins Human genes 0.000 description 10
- 108091005804 Peptidases Proteins 0.000 description 10
- 108010076818 TEV protease Proteins 0.000 description 10
- 238000000684 flow cytometry Methods 0.000 description 10
- 239000012530 fluid Substances 0.000 description 10
- 238000000338 in vitro Methods 0.000 description 10
- 239000002523 lectin Substances 0.000 description 10
- 238000012546 transfer Methods 0.000 description 10
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 9
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 9
- 239000004365 Protease Substances 0.000 description 9
- 238000001261 affinity purification Methods 0.000 description 9
- 238000005119 centrifugation Methods 0.000 description 9
- 238000004581 coalescence Methods 0.000 description 9
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 9
- 238000002156 mixing Methods 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 108010093488 His-His-His-His-His-His Proteins 0.000 description 8
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 8
- 239000008346 aqueous phase Substances 0.000 description 8
- 230000015861 cell surface binding Effects 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 238000000605 extraction Methods 0.000 description 8
- 235000019419 proteases Nutrition 0.000 description 8
- 239000000377 silicon dioxide Substances 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 229920000856 Amylose Polymers 0.000 description 7
- 101710130181 Protochlorophyllide reductase A, chloroplastic Proteins 0.000 description 7
- 150000001413 amino acids Chemical group 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- JQXXHWHPUNPDRT-YOPQJBRCSA-N chembl1332716 Chemical compound O([C@](C1=O)(C)O\C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)/C=C\C=C(C)/C(=O)NC=2C(O)=C3C(O)=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CCN(C)CC1 JQXXHWHPUNPDRT-YOPQJBRCSA-N 0.000 description 7
- 238000010790 dilution Methods 0.000 description 7
- 239000012895 dilution Substances 0.000 description 7
- 239000003995 emulsifying agent Substances 0.000 description 7
- 239000001963 growth medium Substances 0.000 description 7
- 238000009396 hybridization Methods 0.000 description 7
- 125000001165 hydrophobic group Chemical group 0.000 description 7
- 230000003993 interaction Effects 0.000 description 7
- 239000003446 ligand Substances 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 239000002773 nucleotide Substances 0.000 description 7
- 125000003729 nucleotide group Chemical group 0.000 description 7
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 7
- 229920000053 polysorbate 80 Polymers 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- -1 well Substances 0.000 description 7
- 229920000936 Agarose Polymers 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 6
- 108020004705 Codon Proteins 0.000 description 6
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 6
- 239000012980 RPMI-1640 medium Substances 0.000 description 6
- 101710137500 T7 RNA polymerase Proteins 0.000 description 6
- 102100040247 Tumor necrosis factor Human genes 0.000 description 6
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 6
- 239000013592 cell lysate Substances 0.000 description 6
- 238000010276 construction Methods 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 230000005684 electric field Effects 0.000 description 6
- 239000000284 extract Substances 0.000 description 6
- 108020001507 fusion proteins Proteins 0.000 description 6
- 102000037865 fusion proteins Human genes 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 238000007834 ligase chain reaction Methods 0.000 description 6
- 230000036316 preload Effects 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 238000000926 separation method Methods 0.000 description 6
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 6
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 5
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 5
- 108010057466 NF-kappa B Proteins 0.000 description 5
- 102000003945 NF-kappa B Human genes 0.000 description 5
- 239000004793 Polystyrene Substances 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 238000005842 biochemical reaction Methods 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 5
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 5
- 229960003964 deoxycholic acid Drugs 0.000 description 5
- 210000003527 eukaryotic cell Anatomy 0.000 description 5
- 239000000693 micelle Substances 0.000 description 5
- 238000002823 phage display Methods 0.000 description 5
- 229920002223 polystyrene Polymers 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 239000011534 wash buffer Substances 0.000 description 5
- 108091023037 Aptamer Proteins 0.000 description 4
- 230000004544 DNA amplification Effects 0.000 description 4
- 108010008286 DNA nucleotidylexotransferase Proteins 0.000 description 4
- 102100029764 DNA-directed DNA/RNA polymerase mu Human genes 0.000 description 4
- 239000007984 Tris EDTA buffer Substances 0.000 description 4
- 210000000170 cell membrane Anatomy 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 238000010494 dissociation reaction Methods 0.000 description 4
- 230000005593 dissociations Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol Substances OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 230000002209 hydrophobic effect Effects 0.000 description 4
- 239000002502 liposome Substances 0.000 description 4
- 239000006166 lysate Substances 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 238000001000 micrograph Methods 0.000 description 4
- 238000001243 protein synthesis Methods 0.000 description 4
- 230000010076 replication Effects 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 230000009870 specific binding Effects 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 4
- 239000007762 w/o emulsion Substances 0.000 description 4
- 102000000412 Annexin Human genes 0.000 description 3
- 108050008874 Annexin Proteins 0.000 description 3
- 102000012199 E3 ubiquitin-protein ligase Mdm2 Human genes 0.000 description 3
- 108050002772 E3 ubiquitin-protein ligase Mdm2 Proteins 0.000 description 3
- 108700007698 Genetic Terminator Regions Proteins 0.000 description 3
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 3
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 239000012807 PCR reagent Substances 0.000 description 3
- 229930182555 Penicillin Natural products 0.000 description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- 108010067902 Peptide Library Proteins 0.000 description 3
- 239000007801 affinity label Substances 0.000 description 3
- 239000000556 agonist Substances 0.000 description 3
- 229960000723 ampicillin Drugs 0.000 description 3
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 3
- 239000003945 anionic surfactant Substances 0.000 description 3
- 230000001640 apoptogenic effect Effects 0.000 description 3
- 229940098773 bovine serum albumin Drugs 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 3
- 238000006073 displacement reaction Methods 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000012894 fetal calf serum Substances 0.000 description 3
- 108091006047 fluorescent proteins Proteins 0.000 description 3
- 102000034287 fluorescent proteins Human genes 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 108091008147 housekeeping proteins Proteins 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 239000004005 microsphere Substances 0.000 description 3
- 239000002105 nanoparticle Substances 0.000 description 3
- 239000002736 nonionic surfactant Substances 0.000 description 3
- 229940049954 penicillin Drugs 0.000 description 3
- JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 229920000136 polysorbate Polymers 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 210000001995 reticulocyte Anatomy 0.000 description 3
- 239000003161 ribonuclease inhibitor Substances 0.000 description 3
- 238000013207 serial dilution Methods 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 229960005322 streptomycin Drugs 0.000 description 3
- 230000014621 translational initiation Effects 0.000 description 3
- FMYBFLOWKQRBST-UHFFFAOYSA-N 2-[bis(carboxymethyl)amino]acetic acid;nickel Chemical compound [Ni].OC(=O)CN(CC(O)=O)CC(O)=O FMYBFLOWKQRBST-UHFFFAOYSA-N 0.000 description 2
- JBYXPOFIGCOSSB-GOJKSUSPSA-N 9-cis,11-trans-octadecadienoic acid Chemical compound CCCCCC\C=C\C=C/CCCCCCCC(O)=O JBYXPOFIGCOSSB-GOJKSUSPSA-N 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 2
- 241000256844 Apis mellifera Species 0.000 description 2
- 102000004506 Blood Proteins Human genes 0.000 description 2
- 108010017384 Blood Proteins Proteins 0.000 description 2
- 238000000018 DNA microarray Methods 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 102100031780 Endonuclease Human genes 0.000 description 2
- 241001198387 Escherichia coli BL21(DE3) Species 0.000 description 2
- 241000287227 Fringillidae Species 0.000 description 2
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 2
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 2
- 101000577080 Homo sapiens Mitochondrial-processing peptidase subunit alpha Proteins 0.000 description 2
- 101000740659 Homo sapiens Scavenger receptor class B member 1 Proteins 0.000 description 2
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 description 2
- 102000003960 Ligases Human genes 0.000 description 2
- 108090000364 Ligases Proteins 0.000 description 2
- 108060001084 Luciferase Proteins 0.000 description 2
- 102100025321 Mitochondrial-processing peptidase subunit alpha Human genes 0.000 description 2
- DRBBFCLWYRJSJZ-UHFFFAOYSA-N N-phosphocreatine Chemical compound OC(=O)CN(C)C(=N)NP(O)(O)=O DRBBFCLWYRJSJZ-UHFFFAOYSA-N 0.000 description 2
- 206010028851 Necrosis Diseases 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 239000004952 Polyamide Substances 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 108010026552 Proteome Proteins 0.000 description 2
- 108010066717 Q beta Replicase Proteins 0.000 description 2
- 108700008625 Reporter Genes Proteins 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 241000209140 Triticum Species 0.000 description 2
- 235000021307 Triticum Nutrition 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- 238000007846 asymmetric PCR Methods 0.000 description 2
- XIWFQDBQMCDYJT-UHFFFAOYSA-M benzyl-dimethyl-tridecylazanium;chloride Chemical compound [Cl-].CCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 XIWFQDBQMCDYJT-UHFFFAOYSA-M 0.000 description 2
- 239000012148 binding buffer Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229910002091 carbon monoxide Inorganic materials 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 239000000084 colloidal system Substances 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 210000000172 cytosol Anatomy 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 210000001671 embryonic stem cell Anatomy 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N ethyl acetate Substances CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 238000005286 illumination Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
- 238000011901 isothermal amplification Methods 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 230000010807 negative regulation of binding Effects 0.000 description 2
- 229910052759 nickel Inorganic materials 0.000 description 2
- 210000004940 nucleus Anatomy 0.000 description 2
- 230000000737 periodic effect Effects 0.000 description 2
- 229920002647 polyamide Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 210000001236 prokaryotic cell Anatomy 0.000 description 2
- 238000004445 quantitative analysis Methods 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 210000003705 ribosome Anatomy 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 238000001542 size-exclusion chromatography Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000005382 thermal cycling Methods 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- 239000001226 triphosphate Substances 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- 210000005253 yeast cell Anatomy 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- YKBGVTZYEHREMT-KVQBGUIXSA-N 2'-deoxyguanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 YKBGVTZYEHREMT-KVQBGUIXSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- BDEDPKFUFGCVCJ-UHFFFAOYSA-N 3,6-dihydroxy-8,8-dimethyl-1-oxo-3,4,7,9-tetrahydrocyclopenta[h]isochromene-5-carbaldehyde Chemical compound O=C1OC(O)CC(C(C=O)=C2O)=C1C1=C2CC(C)(C)C1 BDEDPKFUFGCVCJ-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- CKTSBUTUHBMZGZ-ULQXZJNLSA-N 4-amino-1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-tritiopyrimidin-2-one Chemical compound O=C1N=C(N)C([3H])=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 CKTSBUTUHBMZGZ-ULQXZJNLSA-N 0.000 description 1
- JYCQQPHGFMYQCF-UHFFFAOYSA-N 4-tert-Octylphenol monoethoxylate Chemical compound CC(C)(C)CC(C)(C)C1=CC=C(OCCO)C=C1 JYCQQPHGFMYQCF-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 244000105975 Antidesma platyphyllum Species 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- CZLRYAPMGGZXQR-RXMQYKEDSA-N C[C@@H]1C2=C1CC=C2 Chemical compound C[C@@H]1C2=C1CC=C2 CZLRYAPMGGZXQR-RXMQYKEDSA-N 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical compound NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 102000004420 Creatine Kinase Human genes 0.000 description 1
- 108010042126 Creatine kinase Proteins 0.000 description 1
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- 238000007399 DNA isolation Methods 0.000 description 1
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 description 1
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 108700006830 Drosophila Antp Proteins 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 241000660147 Escherichia coli str. K-12 substr. MG1655 Species 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 241000724791 Filamentous phage Species 0.000 description 1
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
- MPJKWIXIYCLVCU-UHFFFAOYSA-N Folinic acid Natural products NC1=NC2=C(N(C=O)C(CNc3ccc(cc3)C(=O)NC(CCC(=O)O)CC(=O)O)CN2)C(=O)N1 MPJKWIXIYCLVCU-UHFFFAOYSA-N 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 108700005087 Homeobox Genes Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000257303 Hymenoptera Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 1
- 238000012695 Interfacial polymerization Methods 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 241000272108 Ophiophagus hannah Species 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 108010065868 RNA polymerase SP6 Proteins 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 101710192266 Tegument protein VP22 Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 1
- FJWGYAHXMCUOOM-QHOUIDNNSA-N [(2s,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6s)-4,5-dinitrooxy-2-(nitrooxymethyl)-6-[(2r,3r,4s,5r,6s)-4,5,6-trinitrooxy-2-(nitrooxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-3,5-dinitrooxy-6-(nitrooxymethyl)oxan-4-yl] nitrate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O)O[C@H]1[C@@H]([C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@@H](CO[N+]([O-])=O)O1)O[N+]([O-])=O)CO[N+](=O)[O-])[C@@H]1[C@@H](CO[N+]([O-])=O)O[C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O FJWGYAHXMCUOOM-QHOUIDNNSA-N 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 238000003349 alamar blue assay Methods 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 238000012197 amplification kit Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940124691 antibody therapeutics Drugs 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000003851 biochemical process Effects 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 238000000339 bright-field microscopy Methods 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 239000003990 capacitor Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 108091092328 cellular RNA Proteins 0.000 description 1
- 230000030570 cellular localization Effects 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 229940095074 cyclic amp Drugs 0.000 description 1
- 238000011266 cytolytic assay Methods 0.000 description 1
- 230000032459 dedifferentiation Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 229940008099 dimethicone Drugs 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 210000001163 endosome Anatomy 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 210000005081 epithelial layer Anatomy 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 239000011672 folinic acid Substances 0.000 description 1
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 description 1
- 235000008191 folinic acid Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 235000009424 haa Nutrition 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 210000001822 immobilized cell Anatomy 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 210000004263 induced pluripotent stem cell Anatomy 0.000 description 1
- 230000006882 induction of apoptosis Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000008384 inner phase Substances 0.000 description 1
- 229960001691 leucovorin Drugs 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000007885 magnetic separation Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 230000025608 mitochondrion localization Effects 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 239000002086 nanomaterial Substances 0.000 description 1
- 230000018791 negative regulation of catalytic activity Effects 0.000 description 1
- 210000003061 neural cell Anatomy 0.000 description 1
- 238000007481 next generation sequencing Methods 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 230000005937 nuclear translocation Effects 0.000 description 1
- 238000001668 nucleic acid synthesis Methods 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 230000030648 nucleus localization Effects 0.000 description 1
- 229920002113 octoxynol Polymers 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 108700010839 phage proteins Proteins 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 108010094020 polyglycine Proteins 0.000 description 1
- 229920000232 polyglycine polymer Polymers 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 239000003910 polypeptide antibiotic agent Substances 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 230000018767 positive regulation of catalytic activity Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000012340 reverse transcriptase PCR Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 108010076805 snowdrop lectin Proteins 0.000 description 1
- NRHMKIHPTBHXPF-TUJRSCDTSA-M sodium cholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 NRHMKIHPTBHXPF-TUJRSCDTSA-M 0.000 description 1
- JAJWGJBVLPIOOH-IZYKLYLVSA-M sodium taurocholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 JAJWGJBVLPIOOH-IZYKLYLVSA-M 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1075—Isolating an individual clone by screening libraries by coupling phenotype to genotype, not provided for in other groups of this subclass
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1086—Preparation or screening of expression libraries, e.g. reporter assays
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Computational Biology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261594149P | 2012-02-02 | 2012-02-02 | |
| US61/594,149 | 2012-02-02 | ||
| PCT/US2013/024406 WO2013116698A2 (en) | 2012-02-02 | 2013-02-01 | High throughput screen for biologically active polypeptides |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015506699A JP2015506699A (ja) | 2015-03-05 |
| JP2015506699A5 JP2015506699A5 (enExample) | 2016-03-10 |
| JP6196241B2 true JP6196241B2 (ja) | 2017-09-13 |
Family
ID=47750048
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014555774A Expired - Fee Related JP6196241B2 (ja) | 2012-02-02 | 2013-02-01 | 生物学的に活性なポリペプチドのハイスループットスクリーニング |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US9701959B2 (enExample) |
| EP (1) | EP2809783A2 (enExample) |
| JP (1) | JP6196241B2 (enExample) |
| CA (1) | CA2861387A1 (enExample) |
| WO (1) | WO2013116698A2 (enExample) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10533998B2 (en) | 2008-07-18 | 2020-01-14 | Bio-Rad Laboratories, Inc. | Enzyme quantification |
| US7968287B2 (en) | 2004-10-08 | 2011-06-28 | Medical Research Council Harvard University | In vitro evolution in microfluidic systems |
| EP3913375A1 (en) | 2006-01-11 | 2021-11-24 | Bio-Rad Laboratories, Inc. | Microfluidic devices and methods of use in the formation and control of nanoreactors |
| US9562837B2 (en) | 2006-05-11 | 2017-02-07 | Raindance Technologies, Inc. | Systems for handling microfludic droplets |
| EP2021113A2 (en) | 2006-05-11 | 2009-02-11 | Raindance Technologies, Inc. | Microfluidic devices |
| US8772046B2 (en) | 2007-02-06 | 2014-07-08 | Brandeis University | Manipulation of fluids and reactions in microfluidic systems |
| WO2008130623A1 (en) | 2007-04-19 | 2008-10-30 | Brandeis University | Manipulation of fluids, fluid components and reactions in microfluidic systems |
| US12038438B2 (en) | 2008-07-18 | 2024-07-16 | Bio-Rad Laboratories, Inc. | Enzyme quantification |
| WO2010009365A1 (en) | 2008-07-18 | 2010-01-21 | Raindance Technologies, Inc. | Droplet libraries |
| WO2010111231A1 (en) | 2009-03-23 | 2010-09-30 | Raindance Technologies, Inc. | Manipulation of microfluidic droplets |
| US9399797B2 (en) | 2010-02-12 | 2016-07-26 | Raindance Technologies, Inc. | Digital analyte analysis |
| EP4484577A3 (en) | 2010-02-12 | 2025-03-26 | Bio-Rad Laboratories, Inc. | Digital analyte analysis |
| EP2622103B2 (en) | 2010-09-30 | 2022-11-16 | Bio-Rad Laboratories, Inc. | Sandwich assays in droplets |
| WO2012109600A2 (en) | 2011-02-11 | 2012-08-16 | Raindance Technologies, Inc. | Methods for forming mixed droplets |
| US9150852B2 (en) | 2011-02-18 | 2015-10-06 | Raindance Technologies, Inc. | Compositions and methods for molecular labeling |
| US8658430B2 (en) | 2011-07-20 | 2014-02-25 | Raindance Technologies, Inc. | Manipulating droplet size |
| EP3305918B1 (en) | 2012-03-05 | 2020-06-03 | President and Fellows of Harvard College | Methods for epigenetic sequencing |
| US8975042B2 (en) * | 2012-12-21 | 2015-03-10 | Dna Twopointo, Inc. | Fluorescent and colored proteins and methods for using them |
| US9290552B2 (en) | 2012-12-21 | 2016-03-22 | Dna Twopointo, Inc. | Fluorescent and colored proteins and methods for using them |
| US11901041B2 (en) | 2013-10-04 | 2024-02-13 | Bio-Rad Laboratories, Inc. | Digital analysis of nucleic acid modification |
| US9944977B2 (en) | 2013-12-12 | 2018-04-17 | Raindance Technologies, Inc. | Distinguishing rare variations in a nucleic acid sequence from a sample |
| US20150298091A1 (en) | 2014-04-21 | 2015-10-22 | President And Fellows Of Harvard College | Systems and methods for barcoding nucleic acids |
| LT3456846T (lt) * | 2014-04-21 | 2022-09-12 | President And Fellows Of Harvard College | Nukleorūgšties unikalios sekos įvedimo sistemos ir būdai |
| EP3268462B1 (en) * | 2015-03-11 | 2021-08-11 | The Broad Institute, Inc. | Genotype and phenotype coupling |
| EP3283629A4 (en) | 2015-04-17 | 2018-08-29 | President and Fellows of Harvard College | Barcoding systems and methods for gene sequencing and other applications |
| WO2016187466A1 (en) * | 2015-05-20 | 2016-11-24 | Invenra, Inc. | Methods, apparatus and compositions for expression and high throughput screening |
| WO2017004250A1 (en) | 2015-06-29 | 2017-01-05 | Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University | Systems and methods for continuous flow digital droplet polymerase chain reaction bioanalysis |
| US11965891B2 (en) | 2015-12-30 | 2024-04-23 | Bio-Rad Laboratories, Inc. | Digital protein quantification |
| JP7086856B2 (ja) * | 2016-04-12 | 2022-06-20 | メディミューン,エルエルシー | 免疫レパートリー発掘 |
| KR102657960B1 (ko) * | 2016-10-18 | 2024-04-16 | 삼성전자주식회사 | 힘 전달 프레임 및 이를 포함하는 운동 보조 장치 |
| JP2020500517A (ja) | 2016-11-28 | 2020-01-16 | アリゾナ ボード オブ リージェンツ オン ビハーフ オブ アリゾナ ステート ユニバーシティ | 連続流小滴反応に関連するシステムおよび方法 |
| MY201744A (en) | 2016-12-23 | 2024-03-15 | Visterra Inc | Binding polypeptides and methods of making the same |
| GB2577214B (en) * | 2017-05-05 | 2021-10-06 | Scipio Bioscience | Methods for trapping and barcoding discrete biological units in hydrogel |
| CN118599963A (zh) | 2017-09-22 | 2024-09-06 | 华盛顿大学 | 细胞分子的原位组合标记 |
| WO2019161243A1 (en) * | 2018-02-15 | 2019-08-22 | Enevolv, Inc. | Sensor systems |
| WO2019195197A1 (en) | 2018-04-02 | 2019-10-10 | Dropworks, Inc. | Systems and methods for serial flow emulsion processes |
| WO2020193368A1 (en) * | 2019-03-22 | 2020-10-01 | Qiagen Gmbh | Method for improving the amplification efficiency of bead-based emulsion pcr (empcr) |
| WO2020247976A1 (en) * | 2019-06-03 | 2020-12-10 | Dropworks, Inc. | Systems and methods for stabilizing emulsions |
| CN114829626A (zh) | 2019-10-10 | 2022-07-29 | 1859公司 | 用于微流体筛选的方法和系统 |
| EP4189085A4 (en) * | 2020-07-28 | 2024-08-28 | Protillion Biosciences, Inc. | SYSTEMS AND METHODS FOR TESTING MULTIPLE POLYPEPTIDES |
| EP4200434A4 (en) * | 2020-08-21 | 2024-10-02 | Hifibio (Shanghai) Co., Ltd. | FUNCTIONAL SCREENING USING DROPLET MICROFLUIDIC |
Family Cites Families (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3826364A (en) | 1972-05-22 | 1974-07-30 | Univ Leland Stanford Junior | Particle sorting method and apparatus |
| US4284412A (en) | 1979-07-13 | 1981-08-18 | Ortho Diagnostics, Inc. | Method and apparatus for automated identification and enumeration of specified blood cell subclasses |
| US4498766A (en) | 1982-03-25 | 1985-02-12 | Becton, Dickinson And Company | Light beam focal spot elongation in flow cytometry devices |
| US4661913A (en) | 1984-09-11 | 1987-04-28 | Becton, Dickinson And Company | Apparatus and method for the detection and classification of articles using flow cytometry techniques |
| US4883750A (en) | 1984-12-13 | 1989-11-28 | Applied Biosystems, Inc. | Detection of specific sequences in nucleic acids |
| US4774189A (en) | 1984-12-24 | 1988-09-27 | Flow Cytometry Standards Corp. | Fluorescent calibration microbeads simulating stained cells |
| US4767206A (en) | 1984-12-24 | 1988-08-30 | Flow Cytometry Standards Corporation | Calibration method for flow cytometry using fluorescent microbeads and synthesis thereof |
| US4857451A (en) | 1984-12-24 | 1989-08-15 | Flow Cytometry Standards Corporation | Method of compensating and calibrating a flow cytometer, and microbead standards kit therefor |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US4989977A (en) | 1985-07-29 | 1991-02-05 | Becton, Dickinson And Company | Flow cytometry apparatus with improved light beam adjustment |
| US4714682A (en) | 1985-12-11 | 1987-12-22 | Flow Cytometry Standards Corporation | Fluorescent calibration microbeads simulating stained cells |
| US4800159A (en) | 1986-02-07 | 1989-01-24 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
| AU622104B2 (en) | 1987-03-11 | 1992-04-02 | Sangtec Molecular Diagnostics Ab | Method of assaying of nucleic acids, a reagent combination and kit therefore |
| IL86724A (en) | 1987-06-19 | 1995-01-24 | Siska Diagnostics Inc | Methods and kits for amplification and testing of nucleic acid sequences |
| CA1323293C (en) | 1987-12-11 | 1993-10-19 | Keith C. Backman | Assay using template-dependent nucleic acid probe reorganization |
| EP0359789B1 (en) | 1988-01-21 | 1993-08-04 | Genentech, Inc. | Amplification and detection of nucleic acid sequences |
| CA1340807C (en) | 1988-02-24 | 1999-11-02 | Lawrence T. Malek | Nucleic acid amplification process |
| US5858652A (en) | 1988-08-30 | 1999-01-12 | Abbott Laboratories | Detection and amplification of target nucleic acid sequences |
| US4932207A (en) | 1988-12-28 | 1990-06-12 | Sundstrand Corporation | Segmented seal plate for a turbine engine |
| US5160974A (en) | 1990-06-25 | 1992-11-03 | Flow Science, Inc. | Closed sample cell for use in flow cytometry |
| US5478722A (en) | 1991-02-17 | 1995-12-26 | The Curators Of The University Of Missouri | Preserved cell preparations for flow cytometry and immunology |
| US5846709A (en) | 1993-06-15 | 1998-12-08 | Imclone Systems Incorporated | Chemical process for amplifying and detecting nucleic acid sequences |
| FR2708288B1 (fr) | 1993-07-26 | 1995-09-01 | Bio Merieux | Procédé d'amplification d'acides nucléiques par transcription utilisant le déplacement, réactifs et nécessaire pour la mise en Óoeuvre de ce procédé. |
| US5928905A (en) | 1995-04-18 | 1999-07-27 | Glaxo Group Limited | End-complementary polymerase reaction |
| WO1995033073A1 (en) | 1994-05-28 | 1995-12-07 | Tepnel Medical Limited | Producing copies of nucleic acids |
| US5942391A (en) | 1994-06-22 | 1999-08-24 | Mount Sinai School Of Medicine | Nucleic acid amplification method: ramification-extension amplification method (RAM) |
| WO1996006190A2 (en) | 1994-08-19 | 1996-02-29 | Perkin-Elmer Corporation | Coupled amplification and ligation method |
| US5935825A (en) | 1994-11-18 | 1999-08-10 | Shimadzu Corporation | Process and reagent for amplifying nucleic acid sequences |
| US5843650A (en) | 1995-05-01 | 1998-12-01 | Segev; David | Nucleic acid detection and amplification by chemical linkage of oligonucleotides |
| WO1998004689A1 (en) | 1995-07-31 | 1998-02-05 | Urocor, Inc. | Biomarkers and targets for diagnosis, prognosis and management of prostate disease |
| US5916779A (en) | 1995-09-21 | 1999-06-29 | Becton, Dickinson And Company | Strand displacement amplification of RNA targets |
| US20030215798A1 (en) * | 1997-06-16 | 2003-11-20 | Diversa Corporation | High throughput fluorescence-based screening for novel enzymes |
| US5612473A (en) | 1996-01-16 | 1997-03-18 | Gull Laboratories | Methods, kits and solutions for preparing sample material for nucleic acid amplification |
| US5928906A (en) | 1996-05-09 | 1999-07-27 | Sequenom, Inc. | Process for direct sequencing during template amplification |
| US5939291A (en) | 1996-06-14 | 1999-08-17 | Sarnoff Corporation | Microfluidic method for nucleic acid amplification |
| US5849546A (en) | 1996-09-13 | 1998-12-15 | Epicentre Technologies Corporation | Methods for using mutant RNA polymerases with reduced discrimination between non-canonical and canonical nucleoside triphosphates |
| US5849497A (en) | 1997-04-03 | 1998-12-15 | The Research Foundation Of State University Of New York | Specific inhibition of the polymerase chain reaction using a non-extendable oligonucleotide blocker |
| US5866366A (en) | 1997-07-01 | 1999-02-02 | Smithkline Beecham Corporation | gidB |
| DK1801214T3 (da) | 1997-07-07 | 2011-01-24 | Medical Res Council | In vitro sorteringsfremgangsmåde |
| US5916776A (en) | 1997-08-27 | 1999-06-29 | Sarnoff Corporation | Amplification method for a polynucleotide |
| US5932451A (en) | 1997-11-19 | 1999-08-03 | Incyte Pharmaceuticals, Inc. | Method for unbiased mRNA amplification |
| US6210910B1 (en) | 1998-03-02 | 2001-04-03 | Trustees Of Tufts College | Optical fiber biosensor array comprising cell populations confined to microcavities |
| GB9900298D0 (en) | 1999-01-07 | 1999-02-24 | Medical Res Council | Optical sorting method |
| GB9917027D0 (en) * | 1999-07-20 | 1999-09-22 | Affibody Technology Sweeden Ab | In vitro selection and optional identification of polypeptides using solid support carriers |
| WO2002014860A1 (en) | 2000-08-15 | 2002-02-21 | Discerna Limited | Functional protein arrays |
| GB0022458D0 (en) | 2000-09-13 | 2000-11-01 | Medical Res Council | Directed evolution method |
| GB0127564D0 (en) | 2001-11-16 | 2002-01-09 | Medical Res Council | Emulsion compositions |
| GB0221053D0 (en) | 2002-09-11 | 2002-10-23 | Medical Res Council | Single-molecule in vitro evolution |
| CA2513535C (en) | 2003-01-29 | 2012-06-12 | 454 Corporation | Bead emulsion nucleic acid amplification |
| US20060210982A1 (en) * | 2003-01-31 | 2006-09-21 | Hiroshi Yanagawa | Cleavable assigned molecules and screening method using the same |
| US20060078893A1 (en) | 2004-10-12 | 2006-04-13 | Medical Research Council | Compartmentalised combinatorial chemistry by microfluidic control |
| GB0307428D0 (en) | 2003-03-31 | 2003-05-07 | Medical Res Council | Compartmentalised combinatorial chemistry |
| GB0307403D0 (en) | 2003-03-31 | 2003-05-07 | Medical Res Council | Selection by compartmentalised screening |
| EP1664265A4 (en) | 2003-07-21 | 2009-11-25 | Seng Entpr Ltd | IMPROVED MULTIPLAY PLATE |
| US7585815B2 (en) | 2003-07-24 | 2009-09-08 | Lawrence Livermore National Security, Llc | High throughput protein production screening |
| JP4430076B2 (ja) * | 2003-10-01 | 2010-03-10 | イーティーエイチ・チューリッヒ | ポリペプチドの試験管内進化方法 |
| GB0325653D0 (en) | 2003-11-03 | 2003-12-10 | Medical Res Council | CST emulsions |
| ES2532608T3 (es) | 2003-11-20 | 2015-03-30 | The Board Of Trustees Of The Leland Stanford Junior University | Métodos mejorados de síntesis proteica in vitro |
| EP1691792A4 (en) | 2003-11-24 | 2008-05-28 | Yeda Res & Dev | COMPOSITIONS AND PROCESSES FOR SORTING IN VITRO OF MOLECULE AND CELL LIBRARIES |
| US20050221339A1 (en) | 2004-03-31 | 2005-10-06 | Medical Research Council Harvard University | Compartmentalised screening by microfluidic control |
| US7968287B2 (en) | 2004-10-08 | 2011-06-28 | Medical Research Council Harvard University | In vitro evolution in microfluidic systems |
| GB0511717D0 (en) | 2005-06-09 | 2005-07-13 | Babraham Inst | Repeatable protein arrays |
| WO2009145818A1 (en) * | 2008-03-31 | 2009-12-03 | Pacific Biosciences Of California, Inc | Single molecule loading methods and compositions |
| US8309317B2 (en) | 2008-04-05 | 2012-11-13 | Single Cell Technology, Inc. | Method of screening single cells for the production of biologically active agents |
| WO2010009365A1 (en) | 2008-07-18 | 2010-01-21 | Raindance Technologies, Inc. | Droplet libraries |
| US8312249B1 (en) | 2008-10-10 | 2012-11-13 | Apple Inc. | Dynamic trampoline and structured code generation in a signed code environment |
| CN102549427A (zh) * | 2009-07-07 | 2012-07-04 | 新加坡科技研究局 | 鉴定结合配偶体对的方法 |
| FR2957821B1 (fr) | 2010-03-24 | 2014-08-29 | Inst Francais Du Petrole | Nouvelle zone de regeneration du catalyseur divisee en secteurs pour unites catalytiques regeneratives |
-
2013
- 2013-02-01 EP EP13706121.4A patent/EP2809783A2/en not_active Withdrawn
- 2013-02-01 CA CA2861387A patent/CA2861387A1/en not_active Abandoned
- 2013-02-01 WO PCT/US2013/024406 patent/WO2013116698A2/en not_active Ceased
- 2013-02-01 JP JP2014555774A patent/JP6196241B2/ja not_active Expired - Fee Related
- 2013-02-01 US US14/375,943 patent/US9701959B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| WO2013116698A2 (en) | 2013-08-08 |
| EP2809783A2 (en) | 2014-12-10 |
| US20150018236A1 (en) | 2015-01-15 |
| US9701959B2 (en) | 2017-07-11 |
| CA2861387A1 (en) | 2013-08-08 |
| WO2013116698A3 (en) | 2013-10-17 |
| JP2015506699A (ja) | 2015-03-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6196241B2 (ja) | 生物学的に活性なポリペプチドのハイスループットスクリーニング | |
| Matuła et al. | Single‐cell analysis using droplet microfluidics | |
| Taly et al. | Droplets as microreactors for high‐throughput biology | |
| US20070077572A1 (en) | Compositions and methods for in vitro sorting of molecular and cellular libraries | |
| JP6608368B2 (ja) | 核酸バーコードを用いた単一細胞と関連づけられた核酸の分析方法 | |
| US20130143749A1 (en) | Methods of identifying a pair of binding partners | |
| US20060003347A1 (en) | Single-molecule in vitro evolution | |
| US20030049841A1 (en) | High throughput or capillary-based screening for a bioactivity or biomolecule | |
| CN110520729B (zh) | 用于产生和筛选隔离的肽文库的方法 | |
| JP2005501217A (ja) | 生体活性または生体分子のハイスループットスクリーニングまたはキャピラリーに基づくスクリーニング | |
| AU2002304450A1 (en) | Selective gene amplification | |
| EP1425394A2 (en) | Selective gene amplification | |
| US20150057162A1 (en) | Peptide arrays | |
| Yong et al. | Rapid directed evolution of stabilized proteins with cellular high‐throughput encapsulation solubilization and screening (CHESS) | |
| US20120124685A1 (en) | Compositions and methods for gene expression and chromatin profiling of individual cell types within a tissue | |
| WO2016187466A1 (en) | Methods, apparatus and compositions for expression and high throughput screening | |
| US20240377387A1 (en) | Methods for improving sensitivity of immune profiling using oligo-tagged antigens | |
| US20210214791A1 (en) | Absolute quantification of target molecules at single-entity resolution using tandem barcoding | |
| JP2006211984A (ja) | エマルジョンを利用した核酸増幅方法、及び核酸増幅反応用キット | |
| MXPA00011879A (es) | Construccion y uso de bibliotecas catalogadas de acidos nucleicos que contienen representaciones ventajosamente ajustadas de componentes definidos.. | |
| Schwartz et al. | Assembly of multi-subunit fusion proteins into the RNA-targeting type III-D CRISPR-Cas effector complex | |
| US20250163406A1 (en) | Methods for generating nucleic acid encoded protein libraries and uses thereof | |
| US20230349901A1 (en) | Methods For Identification of Cognate Pairs of Ligands and Receptors | |
| WO2025160372A1 (en) | Methods for identification of cognate pairs of ligands and receptors | |
| JP2023511440A (ja) | 複数の転写産物のハイスループット連結 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160121 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20160121 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20161104 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20170126 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20170403 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170424 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20170728 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20170817 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6196241 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |